PPT-Clinical Breast Cancer Subsets

All Breast Cancers Triple negative 15 Burstein Goldhirsch St Gallen 2007 Hormone Receptor 6575 HER2 1520 1. Dr. Ruth . Heisey. Family Physician/GP Oncologist. Women’s College Hospital/Princess Margaret . Cancer Centre. Clinician Investigator/Associate Professor. University of Toronto. Sandy Fawcett . RN(EC) NP-Adult. October 25,2017. Disclosures. None. Outline. Epidemiology. Risk Factors. Screening. Diagnosis. Treatment. Genetic testing. Research. Epidemiology. 2017 :estimated 252.710 new cases of invasive breast cancer in women. Jennifer M. Matro, MD. Rena Rowan Breast Center. Abramson Cancer Center. University of Pennsylvania. Overview. What is metastatic breast . c. ancer (MBC)?. Who is at risk?. Subtypes of Breast Cancer. Trial Portfolio. Any Receptor Status. Triple Negative. Clinical Trial Contacts. A content placeholder. Use for text, graphics, tables and graphs. You can change this text or delete it.. Here is a placeholder for more text. You may delete this text. Adjuvant or Neoadjuvant. Agustin A Garcia, MD, MMM. Professor of Medicine and Section Chief Hematology Oncology. Charles W . McMullin. III and Richard Paul Grace Chair in Cancer Research. Louisiana State University. . Content. Anatomy of Breast. What is Breast Cancer. Risk Factors. Pathophysiology. Spreading of Breast Cancer. Investigation. Treatment. Nursing care. Preventive care. Introduction. Most common female cancer . U.S. Preventive Services Task Force American Cancer Society American College of Obstetricians and Gynecologists4,5 International Agency for Research on Cancer 7 American College of adiology American L. MEYSKENS, D. (32, 33), and hormonal (42, 46, (60, 78). 57, 66, cancer in is less Klinefelter'n syndrome with male authors measured et al. the formation ofestrone results rerrmin in males been repo Paget ’ Clinical suspicion of Paget ’ s disease 1 PATIENT PRESENTATION Page 1 of 4 Department of Clinical Effectiveness V 8 Approved by Executive Committee of the Medical Staff on 03 / 23 / Eur J Breast Health 2017; 13: 168-74 ABSTRACTBreast cancer is a heterogeneous disease. e purpose of adjuvant therapy for early-stage breast cancer is to provide maximum benet with minimum si 1 : ● Tumor size ● Margin status ● L ymph node status if lymph node surgery performed ● Rule out invasive component ● Nuclear grade ● Histologic type / necrosis ● Estrogen recept Infusion Therapies. Aditya Bardia MD, MPH . Massachusetts General Hospital, . Dana Farber/Harvard Cancer Center,. Harvard Medical School, Boston, MA. .. . No Disclosure. No Relevant Disclosures. . To understand the principle of targeted therapies and importance of routine tumor genotyping in cancer . Key recommendations. 1. National and local workforce planning is essential. Health Education England and all Cancer Alliances should urgently ensure there are enough healthcare professionals to deliver high-quality and timely diagnosis, treatment and care to local women.. 1. Breast Cancer Prepared by:Hai LamLynn YuRacheal Richie Trina Jones2. 3. Pathophysiologyhttp://www.youtube.com/watch?v=YNUBnX9JHQs&feature=relatedhttp://www.youtube.com/watch?v=hswn7HlLkls&feature=related4. Clinical ManifestationsLumpMost...